Press Releases/ News

Rainbow Genomics to Sponsor Exome and Pharmacogenomic Seminars at the Hong Kong Society of Medical Genetics 19th Annual General Meeting cum Scientific Meeting

Seminar: “Clinical Whole Exome Sequencing and Pharmacogenomic Testing for Patients and Healthy Individuals - U.S. & Hong Kong Clinical Perspective”


  • Wayne W. Grody, M.D., Ph.D. Director, Divisions of Medical Genetics and Molecular Diagnostics, UCLA School of Medicine, Los Angeles, California

  • Stephen Lam, M.D. Director of Clinical Genetics Service, Hong Kong Sanatorium and Hospital

Venue: Power A Space, 4/F Tung Hip Commercial Building, 244-248 Des Voeux Road Central, Central, Hong Kong 香港德輔道中244-248號, 東協商業大廈4樓 (Sheung Wan MTR Exit A1)

  • Date: 18 December 2018

  • Time: 6:30-8:30 pm (Reception at 6:00 pm)

Come join us at the HKSMG meeting

San Francisco, November 24, 2018 (Rainbow News Release)

Rainbow Genomics to Present at the Upcoming 68th Annual Meeting of the American Society of Human Genetics

Title: “Mutation spectrum identified by germline testing of hereditary cancers from 500 healthy Chinese individuals using an accessible 30-gene panel following ACMG guidelines”

Date/Location: Tuesday, October 16 - Saturday, October 20, 2018, at the San Diego Convention Center (Room 22) in San Diego, California.

Come join us at the ASHG meeting

San Francisco, October 3, 2018 (Rainbow News Release)

Rainbow Genomics, joining 16 other countries, contributes to Color’s “Genetic Insights into Hereditary Cancer Risk in the Global Population”.

The presentation was given at the 42nd Annual Scientific Meeting of the Human Genetics Society of Australasia.

  • 7952 international hereditary cancer high risk individuals from 17 countries (Argentina, Australia, Belgium, Brazil, Canada, Colombia, Spain, Finland, United Kingdom, Greece, Hong Kong, Ireland, Israel, Japan, Mexico, Peru, Uruguay) received the physician ordered 30-gene or 19-gene Color hereditary cancer test to assess their risk for hereditary cancer. These tests cover breast cancer as well as ovarian, colorectal, melanoma, pancreatic, prostate, uterine and stomach cancers.

  • Globally, the pathogenic mutation rate was 15.6%.

San Francisco, September 17, 2018 (Rainbow News Release)

Rainbow Genomics and Color Genomics Team Up to Provide Access to Affordable Hereditary Cancer and Heart Health Genetic Risk Assessment Tests in Asia

Partnership combines local support with global capabilities to deliver affordable tests to identify genetic mutations associated with an increased risk for hereditary cancer and inherited heart conditions for which early knowledge can make a difference.

San Francisco, May 23, 2018 (Newswire)

Rainbow Genomics Announces the Integration of Clinical Interpretation Services from the UCLA Clinical Genomics Center Supporting Whole Exome Sequencing Tests

The fully-integrated capabilities deliver whole exome sequencing tests covering cardio, adult and pediatric genetic disorders. Clinical reports based on clear medical evidence will be issued by U.S. board-certified medical directors at the UCLA Clinical Genomics Center.

San Francisco, April 26, 2018 (PRWEB)

Baylor Genetics Partners With Rainbow Genomics Offering Adult Wellness Screening and High-Risk Cancer Exome Sequencing Tests in Asian Pacific

Product offering includes adult exome screening, high-risk cancer and wellness cancer tests. 

September 25, 2017 (

OneOme and Rainbow Genomics Team Up to Provide Innovative Genomic Services to Patients in Hong Kong, Japan, and Macau


September 13, 2017